Research To Practice | Oncology Videos

Featuring a slide presentation and related discussion from Dr Angela DeMichele, including the following topics: HER2 and HER3-directed therapies for locally advanced and metastatic breast cancer (0:00) Immunotherapies and antibody-drug conjugates for triple-negative breast cancer and genetic alterations associated with response (13:14) Targeted therapies for estrogen receptor-positive, HER2-negative breast cancer; Response rates by molecular subtypes (25:34) CME information and select publications

Featuring an interview with Dr Angela DeMichele, including the following topics: Staining for HER2 expression and clinical relevance of HER2-0 breast cancer (0:00) Biology of HER2-mutated breast cancer; sequencing of sacituzumab govitecan and trastuzumab deruxtecan for estrogen receptor (ER)-negative breast cancer (4:21) Role of trastuzumab deruxtecan in HER2-low, ER-positive breast cancer; biologic rationale for targeting HER3 with patritumab deruxtecan (11:39) Ongoing clinical trials of tucatinib for HER2-positive locally advanced or metastatic breast cancer: HER2CLIMB-04 and HER2CLIMB-05 (17:16) Recent data with and biomarkers of response for sacituzumab govitecan for triple-negative breast cancer (TNBC); benefits of chemotherapy for disease with a BRCA mutation (22:22) Molecular alterations associated with PARP inhibitor response and potential implications for clinical practice (25:45) Current role of PARP inhibitors, immunotherapy, chemotherapy, and combination therapies for TNBC (28:57) Potential role of sacituzumab govitecan for ER-positive, HER2-negative breast cancer (33:54) Tolerability of capivasertib; using genomic testing to identify tumor subtypes less responsive to endocrine therapy (37:24) Using genomic risk scores to inform treatment for ER-positive, HER2-negative breast cancer that has spread to lymph nodes (43:04) CME information and select publications

Featuring perspectives from Dr Jeff Sharman, including the following topics: Introduction (0:00) Case: A man in his late 50s with progressive small lymphocytic lymphoma who developed acalabrutinib-associated rash — Shams Bufalino, MD (22:14) Case: A man in his late 60s with recurrent deep-vein thrombosis who is receiving warfarin and is diagnosed with chronic lymphocytic leukemia (CLL) requiring treatment — Shaachi Gupta, MD, MPH (27:27) Case: A man in his early 70s with IGHV-unmutated CLL who has severe cardiac disease requiring a defibrillator — Rajalaxmi McKenna, MD (34:45) Case: A man in his early 70s with CLL who remains in remission after treatment with chlorambucil/obinutuzumab — Philip L Brooks, MD (40:43) Case: A man in his early 50s with IGHV-unmutated CLL and del(17p) who developed atrial fibrillation on ibrutinib — Vignesh Narayanan, MD (45:03) Case: A woman in her late 80s with CLL transformed to Hodgkin lymphoma — Spencer H Bachow, MD (51:46) Case: A man in his late 50s with relapsed IGHV-mutated CLL who experienced acalabrutinib-associated headache — Erik Rupard, MD (56:22) Case: A woman in her mid 60s with IGHV-unmutated CLL and hemolytic anemia — Joanna Metzner-Sadurski, MD (1:01:38) CME information and select publications

PARP Inhibition in the Management of Prostate Cancer — Where We Are and Where We're Headed — Faculty Presentation 2: Available Data with, Ongoing Investigation of and Potential Future Role of PARP Inhibitor-Based Combination Strategies — Dr Fred Saad CME information and select publications

PARP Inhibition in the Management of Prostate Cancer — Where We Are and Where We're Headed — Faculty Presentation 1: Optimal Integration of PARP Inhibitor Monotherapy into the Management of Metastatic Castration-Resistant Prostate Cancer — Prof Johann de Bono CME information and select publications

Featuring perspectives from Dr Shannon Westin, including the following topics: Introduction (0:00) Case: A woman in her late 50s with Stage IIIC high-grade serous carcinoma with a gBRCA2 mutation — Gigi Chen, MD (19:58) Case: A woman in her mid 60s with Stage IIA BRCA1/2 wild-type, high-grade serous ovarian adenocarcinoma — Syed M Ahmed, MD, PhD (23:16) Case: A woman in her early 60s with metastatic MSS ovarian carcinoma with a gBRCA1 mutation — Syed Farhan Zafar, MD (30:14) Case: A woman in her early 60s with multiregimen-recurrent advanced ovarian cancer with a gBRCA1 mutation — Rajalaxmi McKenna, MD (39:13) Case: A woman in her early 50s with metastatic hepatoid carcinoma of the ovary with an FGFR fusion — Dr Ahmed (56:54) CME information and select publications

Featuring perspectives from Dr Melissa Johnson, including the following topics: Introduction: KRAS in Lung Cancer (0:00) Case: A woman in her early 60s with adenocarcinoma of the lung and a ROS1 fusion, with bone, brain and leptomeningeal metastases — Gigi Chen, MD (15:52) Case: A man in his late 50s with Stage IVa lung cancer and malignant pleural effusion and a BRAF V600E mutation (PD-L1 60%) — Jiaxin (Jason) Niu, MD, PhD (22:28) Case: A woman in her mid 60s with adenocarcinoma of the lung, a solitary brain metastasis and an ALK fusion — Neil Morganstein, MD (29:33) Case: A woman in her early 50s with metastatic adenocarcinoma of the lung and a RET mutation (PD-L1 TPS 40%) — Rao Mushtaq, MD (36:42) Case: A woman in her early 70s with Stage IV lung adenocarcinoma and malignant pleural effusion and NRG1 fusion — Dr Niu (41:45) Case: A man in his late 60s with metastatic squamous cell carcinoma of the lung with an IDH1 mutation — Sulfi Ibrahim, MD (51:08) MET Exon 14 and HER2 Mutations (54:07) CME information and select publications

Featuring perspectives from Drs Ajai Chari, Elizabeth O'Donnell and Robert Orlowski, including the following topics: Introduction (0:00) Front-Line and Maintenance Treatment Options for Patients with Multiple Myeloma (MM) (2:03) Selection and Sequencing of Therapy for Patients with Relapsed/Refractory MM (28:22) Future Directions in the Management of MM (36:31) CME information and select publications

Featuring perspectives from Prof Eric Van Cutsem, including the following topics: Introduction: Journal Club with Prof Van Cutsem (0:00) Case: A woman in her mid 70s with HER2-negative metastatic gastric cancer (MSI high, PD-L1 >20%) — Nemrata I Peswani, MD (16:51) Case: A man in his mid 70s with multiple comorbidities and HER2-negative metastatic gastroesophageal junction (GEJ) adenocarcinoma (MSS, PD-L1-positive) — Shaachi Gupta, MD, MPD (23:03) Case: A man in his mid 50s with HER2-positive metastatic GEJ adenocarcinoma (PD-L1 low) — Vignesh Narayanan (27:13) Case: A woman in her mid 60s with HER2-equivocal metastatic GEJ adenocarcinoma — Lionel A Kankeu Fonkuoa, MD (30:53) Case: A woman in her mid 60s with HER2-negative metastatic esophageal adenocarcinoma with COPD and vascular disease (pMMR, PD-L1 CPS 5) — Philip L Brooks, MD (46:57) Case: A man in his mid 60s with HER2-negative localized esophageal adenocarcinoma and history of GERD and Barrett's esophagus (pMMR, PD-L1 CPS 1) — Matthew R Strickland, MD (53:18) Case: A man in his early 60s with squamous cell carcinoma of the esophagus who has local and oligometastatic nodal recurrence — Erik Rupard, MD (57:25) CME information and select publications